Tozadenant

Drug Profile

Tozadenant

Alternative Names: A2 (3); A2a-(3); RO4494351; RO4494351-000; RO4494351-002; SYN-115

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Biotie Therapies Corp.
  • Class Amides; Antiparkinsonians; Benzothiazoles; Carboxylic acids; Morpholines; Piperidines; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 16 Feb 2016 Preclinical data released by UCB Pharma
  • 23 Sep 2015 Phase-III clinical trials in Parkinson's disease (Adjunctive treatment) in Czech Republic (PO) (EudraCT2014-005630-60)
  • 21 Jul 2015 Phase-III clinical trials in Parkinson's disease (Adjunctive treatment) in Canada, Spain, Germany (PO) (NCT02453386; 2014-005630-60) after July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top